Zobrazeno 1 - 10
of 31
pro vyhledávání: '"33"'
Autor:
David Cox, J Rege, Linda T. Vahdat, James Song, Lee S. Schwartzberg, Erhan Berrak, Sharon Wilks, Shannon Puhalla, Joyce A. O'Shaughnessy
Publikováno v:
Cancer Research. 73:P4-12
Background: Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, has been approved for patients with metastatic breast cancer (MBC) who have previously received ≥2 chemotherapeutic regimens for MBC. We present final data from a phase 2 s
Autor:
Robert D. Loberg, Katherine Paweletz, Abraham Anderson, Gregory Friberg, Florian D. Vogl, Erick Gamelin, Gloria Juan
Publikováno v:
Cancer Research. 76:439-439
Purpose: Aurora kinases are associated with acquired resistance to therapy in human cancers. We hypothesized that AURKA amplification is a late event in ovarian cancer (OC) progression and that frequency of amplification might be underestimated if as
Autor:
Bernd Gerber, Claus Hanusch, Andreas Schneeweiss, Ingo Bauerfeind, Fergus J. Couch, Dirk-Michael Zahm, Peter Klare, Bianca Lederer, Jenny Furlanetto, Theresa Link, Christian Jackisch, Michael Untch, Jens Huober, Peter A. Fasching, Kristina Lübbe, Valentina Nekljudova, Kerstin Rhiem, Volker Möbus, Christoph Salat, Rita K. Schmutzler, Sibylle Loibl, Hans Tesch, Jens-Uwe Blohmer
Publikováno v:
Cancer Research. 80:P6-10
Background: BRCA1/2 genes play a central role in DNA repair. Therefore, pts harboring gBRCA1/2m treated with chemotherapy might be at higher risk of acute hematological toxicities due to the lower level of functional BRCA1/2 protein potentially resul
Publikováno v:
Cancer Research. 80:P5-10
BACKGROUND: Chemotherapy-induced alopecia (CIA) is a frequent complication that is mostly reversible, however permanent alopecia has been associated with some curative adjuvant regimens. CIA can be decreased through the use of scalp-cooling devices (
Autor:
Laleh Amiri-Kordestani, Sara M. Tolaney, Erik Bloomquist, Rajeshwari Sridhara, R. Pazdur, Shenghui Tang, Eric P. Winer, Diqiong Xie, Julia A. Beaver
Publikováno v:
Cancer Research. 80:PD4-08
Background: The Adjuvant Paclitaxel and Trastuzumab (APT) trial was a single-arm trial in patients with small node-negative HER2-positive early breast cancer (EBC). Although the regimen used in the APT trial has been adopted clinically, single-arm tr
Autor:
Sinan Koca, Ozkan Alan, Faysal Dane, Ilker Nihat Okten, Tugba Akin Telli, Handan Kaya, Nalan Akgul Babacan, Nazım Can Demircan, Perran Fulden Yumuk, Serap Kaya, Mustafa Umit Ugurlu, Bilge Aktas, Tugba Basoglu Tuylu, Rukiye Arikan, Ozlem Ercelep
Publikováno v:
Cancer Research. 80:P2-16
Background: Breast cancer is the most common type of cancer among women in the world. Neoadjuvant chemotherapy is the standard treatment modality in locally advanced disease. Pathological complete response (pCR) is a significant prognostic factor for
Autor:
Monica Fornier, Shanu Modi, Clifford A. Hudis, Chau T. Dang, Theresa Gilewski, Nancy Sklarin, Gabriella D'Andrea, S. Patil, R. Jeselsohn, Andrew D. Seidman, Patrick G. Morris, Jenny C. Chang, A. Abbruzzi
Publikováno v:
Cancer Research. 69:5070-5070
Background: D is an inhibitor of multiple tyrosine kinases; BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. Pre-clinical data show inhibition of BC cell lines; predominantly those of “basal-like” subtype or “triple-negative
Autor:
K Kota, T Sussman, SR Tiwari, Jame Abraham, H Moore, George Thomas Budd, A Montero, S Puhalha
Publikováno v:
Cancer Research. 78:P5-21
Background : The pivotal phase III EMILIA trial reported a progression free survival (PFS) rate of 9.6 months and an objective response rate of 43% with T-DM1 in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab
Autor:
Matthew J. Ellis, Jo Anne Zujewski, Monica M. Mita, J. M. Guenther, Wajeeha Razaq, Anna Weiss, Kelly K. Hunt, T Dockter, Cynthia X. Ma, Olwen Hahn, Lisa A. Carey, Mark A. Watson, S Sanati, Horacio Maluf, Vera J. Suman, Yang Wang, Jeremy Hoog, Kiran Vij, Clifford A. Hudis, Gary Unzeitig, Tina J. Hieken, Amy Tiersten, Eric P. Winer, Ann H. Partridge, Erika C. Crouch, A. Marilyn Leitch, Abigail S. Caudle
Publikováno v:
Cancer Research. 81:GS4-05
Background: Ki67 values >10% 2-4 weeks (wks) after starting neoadjuvant ET (NET) indicates persistent cell proliferation, resistance to ET, and is associated with increased risk of recurrence. The ACOSOG Z1031 trial suggested that these tumors are al
Autor:
Jane Beith, R H de Boer, W Roberts, Michelle White, M Truman, Andrew Redfern, Natasha Woodward
Publikováno v:
Cancer Research. 77:P4-21
Background: Pertuzumab targets the human epidermal growth factor receptor 2 (HER2) through an independent epitope to that of trastuzumab. Improved efficacy with acceptable toxicity has been shown, in metastatic breast cancer (mBC) for pertuzumab in c